Word

G

Status

Dead

Status Code

710

Status Date

Friday, December 7, 2018

Serial Number

85021938

Registration Number

4133826

Registration Date

Tuesday, May 1, 2012

Mark Type

3000

Filing Date

Friday, April 23, 2010

Published for Opposition

Tuesday, February 14, 2012

Cancellation Date

Friday, December 7, 2018

Trademark Owner History

UNIQURE IP B.V. -
Amsterdam Molecular Therapeutics (AMT) IP B.V. - Original Registrant

Classifications

5 Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders and single gene disorders; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers

44 Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation

Color is not claimed as a feature of the mark.
The mark consists of the letter "G" with a dot.

Trademark Events

Dec 7, 2018

Cancelled Sec. 8 (6-Yr)

May 1, 2017

Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Jul 8, 2014

Attorney/Dom.Rep.Revoked And/Or Appointed

Jul 8, 2014

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Jul 2, 2014

Automatic Update Of Assignment Of Ownership

May 1, 2012

Registered-Principal Register

Feb 14, 2012

Official Gazette Publication Confirmation E-Mailed

Feb 14, 2012

Published For Opposition

Jan 25, 2012

Notification Of Notice Of Publication E-Mailed

Jan 10, 2012

Law Office Publication Review Completed

Jan 6, 2012

Approved For Pub - Principal Register

Jan 6, 2012

Examiner's Amendment Entered

Jan 6, 2012

Notification Of Examiners Amendment E-Mailed

Jan 6, 2012

Examiners Amendment E-Mailed

Jan 6, 2012

Examiners Amendment -Written

Jan 5, 2012

Previous Allowance Count Withdrawn

Dec 20, 2011

Withdrawn From Pub - Og Review Query

Dec 6, 2011

Law Office Publication Review Completed

Nov 21, 2011

Approved For Pub - Principal Register

Nov 4, 2011

Teas/Email Correspondence Entered

Nov 4, 2011

Correspondence Received In Law Office

Nov 4, 2011

Teas Response To Office Action Received

May 9, 2011

Notification Of Non-Final Action E-Mailed

May 9, 2011

Non-Final Action E-Mailed

May 9, 2011

Non-Final Action Written

Apr 13, 2011

Teas/Email Correspondence Entered

Apr 13, 2011

Correspondence Received In Law Office

Apr 13, 2011

Teas Response To Office Action Received

Feb 4, 2011

Notification Of Non-Final Action E-Mailed

Feb 4, 2011

Non-Final Action E-Mailed

Feb 4, 2011

Non-Final Action Written

Jan 15, 2011

Teas/Email Correspondence Entered

Jan 15, 2011

Correspondence Received In Law Office

Jan 12, 2011

Assigned To Lie

Dec 22, 2010

Teas Response To Office Action Received

Dec 20, 2010

Teas Response To Office Action Received

Jun 23, 2010

Notification Of Non-Final Action E-Mailed

Jun 23, 2010

Non-Final Action E-Mailed

Jun 23, 2010

Non-Final Action Written

Jun 22, 2010

Assigned To Examiner

Apr 30, 2010

Notice Of Design Search Code Mailed

Apr 29, 2010

New Application Office Supplied Data Entered In Tram

Apr 27, 2010

New Application Entered In Tram